New drug aims to cure chronic hepatitis b in landmark trial
NCT ID NCT06829329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an experimental drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can clear the hepatitis B surface antigen and lower the virus to undetectable levels, potentially leading to a functional cure. Participants will receive AHB-137, standard antivirals, or a placebo, and be followed for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AHB-137 (an experimental drug)
What this could lead to
If successful, this could point toward a functional cure for chronic hepatitis B, where the virus is suppressed and treatment can be stopped.
What could go wrong
This is an early Phase 2 trial with only 105 participants. The drug may not work as hoped, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 401336, China
-
The Third People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, China